Atomic Ai Launches With $35 Million Series A Financing To Advance Ai-Driven Rna Structure Platform For Treating Undruggable Diseases
Atomic Ai Launches With $35 Million Series A Financing To Advance Ai-Driven Rna Structure Platform For Treating Undruggable Diseases
01/25/23, 1:37 PM
Location
san franciscoMoney raised
$35 million
Industry
artificial intelligence
biotechnology
Round Type
series a
Investors
Xu Ventures, Aix Ventures, Uc Berkeley Professor And Arc Institute Co Founder Patrick Hsu, Curai Ceo Neal Khosla, Doug Mohr, Git Hub Ex Ceo Nat Friedman, Ame Cloud Ventures, Not Boring, Greylock, Factory Hq, 8 Vc, Playground Global
Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley professor and Arc Institute Co-founder Patrick Hsu.
Company Info
Location
san francisco, california, united states
Additional Info
Since then, Townshend was quick to add, the company has vastly augmented its models and methods with more raw material, much of which it has created itself in its own wet labs. Fortunately the company has raised a $35 million A round, led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, as well as angels Nat Friedman, Doug Mohr, Neal Khosla, and Patrick Hsu. (The company previously raised a $7 million seed round.) That means Atomic AI is the only one who, publicly at least, has a system that can take a RNA molecule’s raw data in and spit out a reasonably confident estimate of its structure.